Complete response in metastatic breast cancer with visceral crisis using a combination of cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor: A case report from the eastern region of India

Patients with metastatic breast cancer (MBC) in visceral crisis require systemic chemotherapy. However, a coexisting cardiac failure that contradicts the use of systemic chemotherapy often demands an alternative treatment. Here, we report a case of hormone-receptor-positive MBC with cardiological comorbidities. She was treated with a combination treatment of tablet Ribociclib (600 mg once daily for 21 days followed by 7 days gap) and tablet Letrozole (2.5 mg once daily). The patient had a complete metabolic response in 18-Fluorodeoxyglucose Positron Emission tomography-Computed Tomography (18F-FDG PET/CT), after 6 months of treatment. Combination treatment with Ribociclib and Letrozole is beneficial in postmenopausal females with hormone receptor-positive and human epidermal growth factor receptor 2 neu-negative MBC in visceral crisis who have a contraindication to chemotherapy.

Cutaneous and cardiac metastases in carcinoma of anterior tongue

Distant metastases in squamous cell carcinoma of the head and neck are uncommon, and the incidence rises with neck node metastasis. The lung, liver, and bones are the common possible sites for distant metastasis. Cutaneous and cardiac metastases are extremely rare situations with aggressive behaviors and present in the late course of the disease. Here, we report a case of anterior tongue cancer with cutaneous, bone, cardiac, lung, and soft tissue of right suprascapular area metastases after a gap of 2 years of follow-up of completion of treatment with radical surgery and adjuvant concurrent chemoradiation therapy. The present case developed such type of aggressive distant metastases without any locoregional recurrence and died within 6 months of diagnosis of distant metastases

The review of the patterns of presentation and various prognostic factors in male breast cancer patients.

This study was aimed to analyze the patterns of presentation, various prognostic factors and therapeutic modalities for the management of breast cancer in male patients. Thirty cases of male breast cancer were treated with radiotherapy at our department between 1983 and 1997. All the patients were treated with radiotherapy besides surgery (26) and chemotherapy (12). Radical mastectomy was performed in 18 patients, while 6 patients were treated with modified radical mastectomy and 2 patients with simple mastectomy. The post operative radiotherapy was applied at the dose of 50 Gy in 25 fractions over a period of five weeks. The chemotherapy was administered in an adjuvant setting. All the patients were received hormonal therapy. Four patients were lost to follow up. The follow up period ranged from 10-92 months with a median of 38 months. The disease-free survival at 2 and 5 years were 87.7% and 54.67%, respectively. One patient recurred locally, whereas 5 patients had distant metastasis. The age, lymph node status at presentation and presence of distant metastasis were the important prognostic factors. At present, the trend is to treat male breast cancer patients like those of females stage per stage. More randomized studies are required for optimizing therapeutic approach.